实用医学杂志2026，Vol.42Issue(15)：2730-2736,7.DOI:10.3969/j.issn.1006-5725.2026.15.008
RUNX3、P16、DAPK基因启动子DNA甲基化与非小细胞肺癌PD-1抑制剂疗效的关系
Association between promoter DNA methylation of RUNX3,P16 and DAPK genes and efficacy of PD-1 in-hibitors in non-small cell lung cancer
摘要
Abstract
Objective To investigate the association between the promoter DNA methylation of RUNX3,P16,and DAPK genes and the efficacy of programmed death receptor-1(PD-1)inhibitors in patients with non-small cell lung cancer(NSCLC).Methods A total of 73 patients with who NSCLC received treatment with PD-1 inhibi-tors in our hospital from January 2020 to January 2024 were recruited.These patients were then divided into a dis-ease progression group(characterized by progressive disease)and a disease control group(comprising patients with complete response,partial response,and stable disease)based on the therapeutic response.The promoter DNA methylation status of the RUNX3,P16,and DAPK genes in peripheral blood samples,tumor markers,and pulmonary CT features were compared between the two groups.The influencing factors for the sustained disease pro-gression after PD-1 inhibitor therapy were analyzed.Results Among the 73 patients,4 achieved a complete re-sponse,29 achieved a partial response,25 had a stable disease state,and 15 experienced disease progression.The proportion of PD-L1-positive cases was significantly higher in the disease control group compared to that in the dis-ease progression group(P＜0.05).The expression levels of RUNX3,P16,and DAPK were significantly higher in the disease control group than those in the disease progression group(P＜0.05).No statistically significant differ-ences were detected between the two groups in CT features such as lesion density,lesion margin,pleura rela-tionship,vascular signs,ground-glass opacity,calcification,or distal obstructive inflammation(P＞0.05).The serum levels of carcinoembryonic antigen(CEA),neuron-specific enolase(NSE),cytokeratin 19 fragment(CY-FRA21-1),and cancer antigen 125(CA125)showed no significant differences between the groups(P＞0.05).Logistic multivariate regression analysis indicated that RUNX3(OR=0.257,95％CI:0.103-0.644),P16(OR=0.243,95％CI:0.096-0.608),DAPK(OR=0.217,95％CI:0.087-0.543),and PD-L1 positivity(OR=0.242,95％CI:0.096-0.607)were independent influencing factors for sustained disease progression in NSCLC patients after PD-1 inhibitor therapy(P＜0.05).Conclusions Promoter DNA methylation of RUNX3,P16,and DAPK is significantly associated with the efficacy of PD-1 inhibitors in the treatment of NSCLC.More-over,a hypomethylation status is correlated with more favorable therapeutic responses in patients.关键词
非小细胞肺癌/PD-1抑制剂/DNA甲基化Key words
non-small cell lung cancer/PD-1 inhibitor/DNA methylation分类
医药卫生引用本文复制引用
李慧,杨志蓉,王宪伟,冯于卫,敖璐瑶..RUNX3、P16、DAPK基因启动子DNA甲基化与非小细胞肺癌PD-1抑制剂疗效的关系[J].实用医学杂志,2026,42(15):2730-2736,7.基金项目
四川省科技计划项目(编号:2022YFS0222) （编号:2022YFS0222）
